ArticlePLOS global public health2026
Longitudinal analysis of lipid mediators in post-tuberculosis lung disease identifies significant differences.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Post-tuberculosis lung disease (PTLD) is a frequent complication after TB cure, affecting millions globally. Yet, its mechanisms, particularly the role of lipid mediators (LMs) in resolution of inflammation are not clear. This study aimed to identify inflammatory and resolution signatures by comparing longitudinal LM profiles in plasma and exhaled breath condensate (EBC) between TB patients who developed PTLD and those with normal lung recovery.In this prospective cohort study, plasma and EBC were collected at diagnosis and post-TB treatment (generally 6 months). Twenty subjects were selected for analysis following TB treatment, 10 cases (impaired lung function indicative of PTLD) and 10 controls (normal lung function). LM analysis was performed using LC-MS/MS. Group comparisons and longitudinal changes were analyzed using differential abundance analyses (limma) with multiple testing correction with sequential goodness-of-fit adjusted p-values.Baseline plasma analysis showed higher PD1, 12-HEPE, 10-HDoHE, 11-HDoHE, 12-HETE, and 13(14)-EpDPE with significantly lower concentrations of PGA2 in cases vs. controls. Post-treatment, cases had lower AT-RvD6 and 15-oxo-LXA4. Longitudinal plasma analysis with linear modeling showed decreased PD1 in cases during treatment relative to controls. EBC analysis showed no significant differences between group or longitudinal linear comparisons.Distinct systemic lipid mediator profiles and their longitudinal trajectories differ between TB patients who subsequently develop PTLD and those who achieve normal lung recovery. Cases showed an altered LM profile at diagnosis that evolved into a post-treatment state with pro-resolving mediator deficiencies and failed to normalize baseline alterations, suggesting dysregulated resolution pathways in PTLD pathogenesis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.